Close

Publications

Mathematical modelling of the epidemiological impact, budget impact and cost-effectiveness of novel tuberculosis vaccines on multidrug-resistant tuberculosis [Oral Presentation].
WEERASURIYA, C; Harris, R; BOZZANI, F; Gomez, GB; WHITE, R;
2019
International Journal of Tuberculosis and Lung Disease, (2019).23 10
How might novel vaccines for prevention of Tuberculosis disease impact multi-drug resistant tuberculosis burden? A mathematical modelling-based analysis of epidemiologic and health economic impact.
WEERASURIYA, C; Harris, R; SUMNER, T; MCQUAID, C; BOZZANI, F; Knight, G; Gomez, G; WHITE, R;
2019
(2019).
SCHMIDT, W-P; Devamani, CS; Rose, W; ALEXANDER, N; Prakash, JA J;
2019
Tropical Medicine & International Health, (2019).24 12 10.1111/tmi.13322.
CHAN, Y-WD; EDMUNDS, WJ; Chan, H-L; Wong, M-L; Au, K-WA; Chuang, S-K; Van Hoek, AJ; FLASCHE, S;
2019
Human vaccines & immunotherapeutics, (2019).16 3 10.1080/21645515.2019.1663121.
CAREY, ME; Diaz, ZI; Broadstock, M; Bailey, R; Bentsi-Enchill, AD; LARSON, HJ;
2019
CLINICAL INFECTIOUS DISEASES, (2019).69 Suppl 10.1093/cid/ciz483.
Modelling of the Epidemiological Impact of Novel Tuberculosis Vaccines on Multidrug-resistant Tuberculosis in China.
WEERASURIYA, C; Harris, R; SUMNER, T; MCQUAID, C; BOZZANI, F; Knight, G; Gomez, GB; WHITE, R;
2019
(2019).
Pollard, EJ M; PATTERSON, C; Russell, TL; Apairamo, A; Oscar, J; Arcà, B; DRAKELEY, C; Burkot, TR;
2019
Malaria journal, (2019).18 1 10.1186/s12936-019-2975-8.
Design of Vaccine Efficacy Trials for Priority Emerging and Epidemic Diseases.
Watson, C; Ferguson, N; Donnelly, C; Keeling, M; Tildesley, M; Horby, P; EDMUNDS, J;
2019
TRIALS, (2019).20,